Summary
This study is looking at how the body processes medicines in young people with cancer, and how this can change during treatment. This is sometimes called “phenoconversion”, which means your body may handle medicines differently over time.
This study is not testing a new cancer treatment. Instead, it is looking at whether it is feasible to use small doses of commonly used “probe” medicines to understand how the body processes drugs during cancer treatment.
Who can take part
This study is for children, teenagers, and young adults aged 6 to 25 years who have Hodgkin lymphoma or non-Hodgkin lymphoma.
What the study involves
Participants will be given small doses of “probe” medicines that help researchers understand how the body breaks down drugs.
These medicines (omeprazole and dextromethorphan) will be taken at times that match the participant’s regular hospital visits, so no extra visits are needed. Blood samples will be taken to measure how the body processes these medicines.
Why this study is important
This study will help researchers understand whether this type of testing is practical and acceptable for young people with cancer.
In the future, this research may help doctors tailor treatments more precisely to each person, improving how well medicines work and reducing side effects.